TW201035081A - Novel pharmaceutical composition for treatment of schizophrenia - Google Patents

Novel pharmaceutical composition for treatment of schizophrenia Download PDF

Info

Publication number
TW201035081A
TW201035081A TW099109850A TW99109850A TW201035081A TW 201035081 A TW201035081 A TW 201035081A TW 099109850 A TW099109850 A TW 099109850A TW 99109850 A TW99109850 A TW 99109850A TW 201035081 A TW201035081 A TW 201035081A
Authority
TW
Taiwan
Prior art keywords
group
lower alkyl
substituted
aryl
alkyl group
Prior art date
Application number
TW099109850A
Other languages
English (en)
Chinese (zh)
Inventor
Shinji Takahashi
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of TW201035081A publication Critical patent/TW201035081A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW099109850A 2009-03-31 2010-03-31 Novel pharmaceutical composition for treatment of schizophrenia TW201035081A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2660962A CA2660962A1 (en) 2009-03-31 2009-03-31 Novel pharmaceutical composition for treatment of schizophrenia

Publications (1)

Publication Number Publication Date
TW201035081A true TW201035081A (en) 2010-10-01

Family

ID=42269730

Family Applications (1)

Application Number Title Priority Date Filing Date
TW099109850A TW201035081A (en) 2009-03-31 2010-03-31 Novel pharmaceutical composition for treatment of schizophrenia

Country Status (7)

Country Link
EP (1) EP2413940A1 (enExample)
JP (1) JP2012521963A (enExample)
KR (1) KR20120004488A (enExample)
CN (1) CN102378630A (enExample)
CA (1) CA2660962A1 (enExample)
TW (1) TW201035081A (enExample)
WO (1) WO2010114163A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103351348A (zh) * 2013-07-15 2013-10-16 黄河三角洲京博化工研究院有限公司 一种2-甲胺基嘧啶盐酸盐的合成方法
KR200492485Y1 (ko) 2016-02-16 2020-10-23 주식회사 마르시끄 일회용 마스카라

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1982799A (en) 1998-01-23 1999-08-09 Yamanouchi Pharmaceutical Co., Ltd. Novel potassium channel protein
MXPA03005609A (es) 2000-12-21 2003-10-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
MXPA04007590A (es) * 2002-02-05 2004-12-06 Yamanouchi Pharma Co Ltd Derivado de 2,4,6-triamino-1,3,5-triacina.
US8101380B2 (en) * 2007-03-26 2012-01-24 The United States Of America As Represented By The Secretary Of Health And Human Services Schizophrenia-related isoform of KCNH2 and development of antipsychotic drugs

Also Published As

Publication number Publication date
KR20120004488A (ko) 2012-01-12
CN102378630A (zh) 2012-03-14
CA2660962A1 (en) 2010-09-30
JP2012521963A (ja) 2012-09-20
EP2413940A1 (en) 2012-02-08
WO2010114163A1 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
US20220202798A1 (en) Use of pridopidine for the treatment of fragile x syndrome
EP3606525B1 (en) Compositions for treating aging-associated impairments using ccr3-inhibitors
CA2850707C (en) Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
AU2018383098B2 (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
CA2957224A1 (en) Method of treating prader-willi syndrome
CN116687906A (zh) ANAVEX2-73的对映体及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途
CN115175911A (zh) 用于治疗认知损害的苯二氮䓬衍生物、组合物和方法
KR20160088886A (ko) 자폐증 스펙트럼 장애의 치료에 사용되는 도파민 ｄ3 수용체 길항제로서의 크로모네 유도체
CN108348524A (zh) 用于从中风恢复的方法和组合物
TW201035081A (en) Novel pharmaceutical composition for treatment of schizophrenia
RS60849B1 (sr) Trostruka kombinacija čistih antagonista receptora 5-ht6, inhibitora acetilholinesteraze i antagonista receptora nmda
US20100256152A1 (en) Novel pharmaceutical composition for treatment of schizophrenia
BR112021004938A2 (pt) métodos e composições para tratamento de danos associados com o envelhecimento usando inibidores de ccr3
ES3036880T3 (en) Combinations of masupirdine with donepezil or memantine for treating behavioral and psychological symptoms in patients with dementia
Class et al. Patent application title: USE OF PRIDOPIDINE FOR THE TREATMENT OF FRAGILE X SYNDROME Inventors: Michael Hayden (Herzliya, IL) Mahmoud Abdulhossein Pouladi (Singapore, SG) Assignees: PRILENIA NEUROTHERAPEUTICS LTD. NATIONAL UNIVERSITY OF SINGAPORE Agency For Science, Technology and Research
RU2799049C2 (ru) Способы лечения изменений поведения
HK40071167A (en) Methods for treating behavioral and psychological symptoms in patients with dementia
TW200918059A (en) Nerve cell death inhibiting agent
HK40016661A (en) Pridopidine for use in the treatment of fragile x syndrome
HK40016661B (en) Pridopidine for use in the treatment of fragile x syndrome
BRPI0901286A2 (pt) nova composição farmacêutica para o tratamento da esquizofrenia
JP2017039645A (ja) 網膜疾患の予防又は治療のための医薬
EA012033B1 (ru) Применение дезоксипеганина для лечения шизофренических психозов